Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 190

The DOI matches its Crossref record.

Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.

Primrose, John Neil, Fox, Richard, Palmer, Daniel H., Prasad, Raj, Mirza, Darius, Anthoney, David Alan, Corrie, Philippa, Falk, Stephen, Wasan, Harpreet Singh, Ross, Paul J., Wall, Lucy R., Wadsley, Jonathan, Evans, T.R. Jeffry, Stocken, Deborah, Praseedom, Raaj, Cunningham, David, Garden, O James, Stubbs, Clive, Valle, Juan W., Bridgewater, John A.·2017·Journal of Clinical Oncology

Abstract

4006 Background: Despite improvements in multidisciplinary management, BTC has a poor outcome. Approximately 20% of cases are suitable for surgical resection with a 5 year survival of < 10%. BILCAP aimed to determine whether capecitabine (Cape) improves overall survival (OS) compared to observation (Obs) following radical surgery. Methods: Patients with completely-resected cholangiocarcinoma (CCA) or gallbladder cancer (including liver and pancreatic resection, as appropriate), with adequate biliary drainage, no ongoing infection, adequate renal, haematological and liver function, and ECOG PS ≤2, were randomized 1:1 to Cape (1250 mg/m 2 D1-14 every 21 days, for 8 cycles) or Obs. Randomization was minimized on tumor site, resection status, ECOG PS and surgical center. The primary outcome was OS in the intention to treat (ITT) population. 410 patients were needed to detect a hazard ratio (HR) of 0.69 (2-sided α = 0.05 and 80% power). HR was estimated by Cox survival model with adjustment for the minimization factors. Primary analysis performed with at least 24 months (m) follow-up. Results: 447 participants were randomized to Cape (n = 223) or Obs (n = 224) from 44 UK sites between 2006-2014. Median age was 63y (IQR 55, 69) and 201 (45%), 232 (52%), and 14 (3%) patients were ECOG PS 0, 1 and 2 respectively. Primary site: 84 (19%) intrahepatic, 128 (28%) hilar, 156 (35%) extrahepatic CCA and 79 (18%) muscle-invasive gallbladder cancers. Resection margins: R0 in 279 (62%) and R1 in 168 (38%); 207 (46%) were node-negative. Follow up was at least 36m in > 80% of surviving patients. By ITT analysis (n = 447), median OS was 51m (95%CI 35, 59) for Cape and 36m (95%CI 30, 45) for Obs, HR 0.80 (95%CI 0.63, 1.04; p = 0.097). Sensitivity analyses with adjustment for nodal status, grade of disease and gender indicated HR 0.71 (95%CI 0.55, 0.92 p < 0.01). In the per-protocol analysis (Cape n = 210, Obs n = 220) median OS was 53m (95%CI 40, NR) for Cape and 36m (95%CI 30, 44) for Obs, HR 0.75 (95%CI 0.58, 0.97; p = 0.028). Median RFS (ITT) was 25m (95%CI 19, 37) for Cape and 18m (95%CI 13, 28) for Obs. Grade 3-4 toxicity was less than anticipated. Conclusions: Cape improves OS in BTC when used as adjuvant and should become standard of care. Clinical trial information: ISRCTN72785446.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.35.15_suppl.4006

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 190

Metadata

Authors
Primrose, J. N., Fox, R., Palmer, D. H., Prasad, R., Mirza, D., Anthoney, D. A., Corrie, P., Falk, S., Wasan, H. S., Ross, P. J., Wall, L. R., Wadsley, J., Evans, T. R. J., Stocken, D., Praseedom, R., Cunningham, D., Garden, O. J., Stubbs, C., Valle, J. W., & Bridgewater, J. A.
Venue
Journal of Clinical Oncology
Published
2017-05-20
Volume
35
Issue
15_suppl
Pages
4006-4006
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2725911379
Cited by
190
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. https://app.cochat.ai/papers/10.1200/jco.2017.35.15_suppl.4006
The paper
Primrose, J. N., Fox, R., Palmer, D. H., Prasad, R., Mirza, D., Anthoney, D. A., Corrie, P., Falk, S., Wasan, H. S., Ross, P. J., Wall, L. R., Wadsley, J., Evans, T. R. J., Stocken, D., Praseedom, R., Cunningham, D., Garden, O. J., Stubbs, C., Valle, J. W., & Bridgewater, J. A. (2017). Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.35.15_suppl.4006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.